ClinicalTrials.gg
CompletedNCT04358432Updated Mar 2, 2023

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

A Phase 2 interventional study of AK102 and Placebos in Hypercholesterolemia, sponsored by Akeso. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
262
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
22nd of 53
262 · median 207
Started
2020
with 2 others
Phase 2
6 of 59
none open now
Registered
26th of 59
by date
Lead sponsor
3 of 59
Akeso

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 22nd largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2020, is one of 6 in phase 2, and was the 26th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .

The primary objective of this study is to evaluate the efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form (ICF), and be able to comply with the treatment plan, visit, laboratory examination and other requirements specified in the study;
  2. Age ≥ 18, male or female;
  3. According to the guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016), subjects assessed as very high risk or high risk of cardiovascular disease;
  4. Subjects received stable and optimal dose of statins for at least 4 weeks before randomization, either in combination with or without ezetimibe;
  5. The blood lipid level of the patients with stable 4-week basic lipid-lowering drug treatment met one of the following conditions by the central laboratory test: LDL-C level in very high risk subjects > 1.8 mmol / L (70 mg / dl) or LDL-C level of high-risk subjects > 2.6 mmol / L (100 mg / dl)
  6. TG ≤ 4.5 mmol / L (400 mg / dl) measured by central laboratory at screening;

Exclusion criteria

Exclusion Criteria:

  1. Has received cholesterol ester transfer protein (CETP) inhibitor within12 months prior to randomization;
  2. Has received PCSK9 inhibitors or are known to be allergic to PCSK9 inhibitors or their components;
  3. Has received other drugs within 4 weeks or within 5 half lives (whichever was longer) prior to screening.
  4. Has previously received biological agent treatment, organ transplantation or gene therapy;
  5. Abnormal laboratories prior to the first study drug administration: or AST> 3 × ; Creatine kinase > 5 × ULN; \<= 30 ml/min/1.73m2 by method;
  6. Uncontrolled hypothyroidism or hyperthyroidism defined as TSH \< 1.0 ×LLN or > 1.5 × ULN, respectively;
  7. Myocardial infarction, unstable angina pectoris, percutaneous coronary intervention (PCI), coronary bypass grafting (CABG), stroke, severe deep vein thrombosis or pulmonary embolism, or severe arrhythmia occurred within three months prior to randomization ;
  8. Grade III or IV according to assessment;
  9. Planned to have heart-related surgery within 3 months after randomization;
  10. Type 1 diabetes or poorly controlled type 2 diabetes [ > 8.5% within 1 month];
  11. Subjects with hypertension that could not be controlled by drugs;
  12. Known concomitant diseases that may lead to secondary hyperlipidemia, including nephrotic syndrome, cholestatic liver failure, etc;
  13. Positive or antibody;
  14. Known history of primary immunodeficiency virus infection or positive (HIV) test;
  15. History of drug or alcohol abuse prior to screening;
  16. Has taken the following drugs within 6 weeks prior to screening: red koji rice > 200 mg/day; niacin > 1000 mg/day; omega-3 fatty acids; or prescription lipid regulating drugs ; cholesterol lowering drugs, health care products, Chinese patent medicines or other food additives other than statins and ezetimibe;
  17. Has taken the following drugs within 3 months prior to screening: systemic cyclosporine, systemic steroids, vitamin A derivatives and retinol derivatives for the treatment of skin diseases (such as retinoic acid).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
262 participants (actual)

Study arms

  • Experimental
    AK102 450 mg

    Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Experimental
    AK102 300 mg

    Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Experimental
    AK102 150 mg

    Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Experimental
    AK102 75 mg

    Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Placebo comparator
    Placebo Q4W

    Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks

    Drug: Placebos · Drug: Statins and/or Ezetimibe

  • Placebo comparator
    Placebo Q2W

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks

    Drug: Placebos · Drug: Statins and/or Ezetimibe

Interventions

  • DrugAK102

    Administered by subcutaneous injection

  • DrugPlacebos

    Administered by subcutaneous injection

  • DrugStatins and/or Ezetimibe

    Drug pages: Statins · Ezetimibe

    Lipid-lowering therapies

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 12

    Time frame: At baseline and week 12

Secondary outcomes

  1. Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)

    Time frame: From baseline through 12 weeks

  2. Percent change from baseline in high-density lipoprotein cholesterol (HDL-C)

    Time frame: From baseline through 12 weeks

  3. Percent change from baseline in non High-density lipoprotein (non-HDL) cholesterol

    Time frame: From baseline through 12 weeks

  4. Percent change from baseline in serum Triglyceride (TG) cholesterol

    Time frame: From baseline through 12 weeks

  5. Percent change from baseline in Apolipoprotein B (Apo B)

    Time frame: From baseline through 12 weeks

  6. Percent change from baseline in Apolipoprotein A-I (ApoA-I)

    Time frame: From baseline through 12 weeks

  7. Percent change from baseline in Lipoprotein(a) [Lp-(a)]

    Time frame: From baseline through 12 weeks

  8. Percent change from baseline in Total Cholesterol(TC)

    Time frame: From baseline through 12 weeks

  9. Incidence of treatment-emergent adverse events

    Time frame: From baseline through 12 weeks

  10. Serum concentrations of AK102

    Time frame: From baseline through 12 weeks

  11. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.

    Time frame: From baseline through 12 weeks

  12. Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9)

    Time frame: From baseline through 12 weeks

07

Study locations

2 sites
  • Zhong Shan Hosipital Fu Dan University
    Shanghai, 200032, China
  • Affiliated hospital of Guangdong medical university
    Zhanjiang, 524000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Feb 2021, 9 months.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 9 months is close to that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
Apr 24, 2020
StartActual
May 13, 2020
Primary completionActual
Feb 25, 2021
CompletionActual
Feb 25, 2021
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04358432
Lead sponsor
Akeso
Collaborators
AD Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
May 13, 2020
Primary completion
Feb 25, 2021
Completion
Feb 25, 2021
Last update
Mar 2, 2023

Study contacts

Junbo Ge, MD
principal investigator · Zhong Shan Hospital Fu Dan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion